Skip to main content

and
  1. Article

    Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

    Mohsen Malehmir, Dominik Pfister, Suchira Gallage, Marta Szydlowska in Nature Medicine (2022)

  2. Article

    Open Access

    NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Hepatocellular carcinoma (HCC) can have viral or non-viral causes15. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stra...

    Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere in Nature (2021)

  3. No Access

    Article

    Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

    Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, w...

    Mohsen Malehmir, Dominik Pfister, Suchira Gallage, Marta Szydlowska in Nature Medicine (2019)